| scholarly article | Q13442814 |
| P50 | author | David C. Montefiori | Q63302725 |
| P2093 | author name string | K Reed Clark | |
| Philip R Johnson | |||
| Anne D Lewis | |||
| Ruju Chen | |||
| P2860 | cites work | A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals | Q24560010 |
| Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies | Q29614531 | ||
| Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
| Strategies for selection of antibodies by phage display | Q32093051 | ||
| Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. | Q33647300 | ||
| Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin | Q33735882 | ||
| Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins | Q33783353 | ||
| Characterization of primary isolate-like variants of simian-human immunodeficiency virus | Q33825229 | ||
| Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development | Q33842152 | ||
| Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro | Q33853775 | ||
| Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. | Q33870236 | ||
| The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity | Q33961624 | ||
| Biological considerations in the development of a human immunodeficiency virus vaccine | Q33983937 | ||
| Adeno-associated virus vectors for gene therapy: more pros than cons? | Q34080580 | ||
| Preventive and therapeutic strategies for respiratory syncytial virus infection | Q34476175 | ||
| Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys | Q35674907 | ||
| The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate | Q35869892 | ||
| Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector | Q35872651 | ||
| Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein | Q35943644 | ||
| Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus | Q36159178 | ||
| Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors | Q36734619 | ||
| Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design | Q36872332 | ||
| Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. | Q39457063 | ||
| The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region | Q39602963 | ||
| Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation. | Q39606539 | ||
| Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. | Q40191379 | ||
| Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. | Q40832863 | ||
| A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors | Q40918962 | ||
| Cell lines for the production of recombinant adeno-associated virus | Q41286219 | ||
| gp120: Biologic aspects of structural features | Q43908516 | ||
| Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. | Q44022556 | ||
| Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). | Q45012988 | ||
| Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia | Q45060641 | ||
| Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen | Q45742861 | ||
| Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection | Q45744790 | ||
| Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses | Q45749766 | ||
| Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group | Q45757638 | ||
| Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins | Q45762836 | ||
| Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors | Q45873434 | ||
| In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells | Q45882573 | ||
| Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody | Q46352552 | ||
| Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination | Q73097737 | ||
| Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle | Q73254110 | ||
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 8769-8775 | |
| P577 | publication date | 2002-09-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer | |
| P478 | volume | 76 |
| Q40384910 | A combination of mutations enhances the neurotropism of AAV-2. |
| Q37498000 | AAV Vectors Vaccines Against Infectious Diseases. |
| Q27318266 | AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity |
| Q92111662 | AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region |
| Q34464133 | AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges |
| Q38196689 | Adeno-associated virus delivery of broadly neutralizing antibodies |
| Q57062356 | Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1 |
| Q37145022 | Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge |
| Q37645048 | An oncolytic adenovirus that expresses the HAb18 and interleukin 24 genes exhibits enhanced antitumor activity in hepatocellular carcinoma cells |
| Q39108774 | Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention |
| Q30408097 | Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies |
| Q35658856 | Antibody-based protection against HIV infection by vectored immunoprophylaxis |
| Q35914292 | Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection |
| Q38794293 | Cell and gene therapy strategies to eradicate HIV reservoirs |
| Q33293219 | Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models |
| Q30425594 | Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies |
| Q27657585 | Crystal structure of a 3B3 variantâ A broadly neutralizing HIV-1 scFv antibody |
| Q40077818 | Current progress in innovative engineered antibodies |
| Q82267564 | DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells |
| Q37069837 | Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. |
| Q97545395 | Development of vaccines against the sexually transmitted infections gonorrhoea, syphilis, Chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus |
| Q26783764 | Emerging Vaccine Technologies |
| Q30490945 | Engineering antibody-like inhibitors to prevent and treat HIV-1 infection |
| Q38717198 | Engineering broadly neutralizing antibodies for HIV prevention and therapy |
| Q26800101 | Engineering humoral immunity as prophylaxis or therapy |
| Q39611325 | Expression of enhancing-activity-free neutralizing antibody against dengue type 1 virus in plasmid-inoculated mice |
| Q39425614 | Fight fire with fire: Gene therapy strategies to cure HIV. |
| Q58604627 | Genetic Strategies for HIV Treatment and Prevention |
| Q56929067 | Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV |
| Q28660580 | IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA |
| Q38314210 | In situ production of therapeutic monoclonal antibodies |
| Q36440069 | Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice |
| Q47986812 | Monoclonal antibodies produced by muscle after plasmid injection and electroporation |
| Q35677620 | Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas |
| Q36603515 | Neutralizing antibodies to HIV-1 induced by immunization. |
| Q37743813 | Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques |
| Q30358434 | Passive immunization against HIV/AIDS by antibody gene transfer. |
| Q45236555 | Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody |
| Q38981274 | Prolonged expression of an anti-HIV-1 gp120 minibody to the female rhesus macaque lower genital tract by AAV gene transfer |
| Q34110625 | Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VHH-based antitoxin protein |
| Q94547060 | Promise and Progress of an HIV-1 Cure by Adeno-Associated Virus Vector Delivery of Anti-HIV-1 Biologics |
| Q46866119 | Rapid/sustained anti-anthrax passive immunity mediated by co-administration of Ad/AAV. |
| Q33937285 | Rational antibody-based HIV-1 vaccine design: current approaches and future directions |
| Q37937369 | Recent developments for Pseudomonas vaccines |
| Q36058890 | Recombinant AAV Vectors for Enhanced Expression of Authentic IgG. |
| Q24806498 | Regulatable systemic production of monoclonal antibodies by in vivo muscle electroporation |
| Q27487961 | Sang Froid in a time of trouble: is a vaccine against HIV possible? |
| Q45592468 | Sequence analysis, viral rescue from infectious clones and generation of recombinant virions of the avian adeno-associated virus |
| Q39455602 | Single-chain Fv-based anti-HIV proteins: potential and limitations |
| Q40434248 | Stable antibody expression at therapeutic levels using the 2A peptide |
| Q38737706 | State of play and clinical prospects of antibody gene transfer |
| Q38019332 | The design and evaluation of HIV-1 vaccines |
| Q33902499 | The potential of adeno-associated viral vectors for gene delivery to muscle tissue |
| Q34344211 | Therapeutic antibody gene transfer: an active approach to passive immunity |
| Q37397574 | Towards a genetic AIDS vaccine |
| Q37295534 | Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys |
| Q35664155 | Vectored antibody gene delivery for the prevention or treatment of HIV infection |
| Q40040079 | Vectored immunoprophylaxis: an emerging adjunct to traditional vaccination |
| Q58605707 | mRNA as novel technology for passive immunotherapy |
| Q40088616 | mRNA mediates passive vaccination against infectious agents, toxins, and tumors. |
Search more.